



HAL
open science

Letter: the use of magnetic resonance scores (Anali) for risk stratification in PSC

Sara Lemoine, Nora Cazzagon, Olivier Chazouillères, Christophe Corpechot,
Lionel Arrivé

► To cite this version:

Sara Lemoine, Nora Cazzagon, Olivier Chazouillères, Christophe Corpechot, Lionel Arrivé. Letter: the use of magnetic resonance scores (Anali) for risk stratification in PSC. *Alimentary Pharmacology & Therapeutics (Suppl)*, 2021, 53 (12), pp.1329-1330. 10.1111/apt.16378 . hal-03985305

HAL Id: hal-03985305

<https://hal.sorbonne-universite.fr/hal-03985305>

Submitted on 13 Feb 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

About the use of magnetic resonance scores (Anali) for risk stratification in PSC

Sara Lemoine^{1,2}, Nora Cazzagon³, Olivier Chazouillères^{1,2}, Christophe Corpechot^{1,2}, Lionel Arrivé⁴

Affiliations :

¹Assistance Publique-Hôpitaux de Paris, Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis (CRM, MIVB-H), Department of Hepatology, Saint-Antoine Hospital, Paris, France;

²Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA) and Institute of Cardiometabolism and Nutrition (ICAN), Paris, France;

³Department of Surgery Oncology and Gastroenterology (DiSCOG), University of Padova, Padova, Italy;

⁴Assistance Publique-Hôpitaux de Paris, Department of Radiology, Saint-Antoine Hospital, Paris, France;

Corresponding author:

Sara Lemoine, MD, PhD

Hepatology Department Saint-Antoine Hospital, 75012 Paris, France

sara.lemoine@aphp.fr

Telephone + 33 1 49 28 29 23 Fax + 33 1 49 28 21 07

Abbreviations:

GBCA gadolinium-based contrast agent

MR magnetic resonance

MRC magnetic resonance cholangiography

PSC primary sclerosing cholangitis

VCTE vibration controlled transient elastography

Dear editor,

We read with interest the review written by Mahzar and Russo about non-invasive prognostic tests for primary sclerosing cholangitis (PSC)¹. Although rare, PSC is a serious disease, associated with potentially lethal complications, notably cirrhosis and cholangiocarcinoma². Liver transplantation is the only curative treatment for PSC and median transplant-free survival is approximately 12-21 years after diagnosis³. Identification of prognostic factors is essential for tailoring the follow-up strategies and testing new therapeutic modalities in homogeneous groups of PSC patients. As detailed in this review, over the last twenty years, different teams across the world, including ours, have identified several non-invasive prognostic tests for PSC patients¹. First, our team demonstrated in a large retrospective study that liver stiffness measured by vibration-controlled transient elastography (VCTE) was an independent predictive marker of survival in PSC patients⁴. Next, we built 2 magnetic resonance (MR) risk scores (with and without gadolinium-based contrast agent (GBCA) administration)⁵, called Anali scores, and showed that they were able to predict adverse outcome-free survival (defined by survival without liver transplantation or cirrhosis

decompensation) in two large international independent cohorts of PSC patients⁶. Furthermore, we showed that Anali score without GBCA and VCTE have a complementary prognostic value, so that their use in combination allows easy risk stratification of PSC patients⁷. In their review, Mazhar and Russo compared the prognostic performance of 8 different non-invasive tests and showed that Anali scores were the second best prognostic markers after the PSC Risk Estimate Tool (PREsTo)⁸. However, the comparison of the area under the curve of the prognostic tests is methodologically debatable because the design of the studies and their primary outcomes were different.

Carried by their enthusiasm, Mahzar and Russo wrote in their abstract that Anali scores are associated with the development of cholangiocarcinoma. However, in our studies (Anali scores with or without VCTE), the occurrence of cholangiocarcinoma was not recorded as an adverse outcome, but only the death or liver transplantation, that can potentially be caused by cholangiocarcinoma^{6, 7}. This correction is important to be made for the appropriate use of Anali scores. Since surveillance for hepatobiliary cancer was reported to improve outcomes in PSC⁹, MR cholangiography (MRC) is recommended for systematic surveillance of PSC patients¹⁰. However, no MRC features in PSC have been shown to associate with the risk of developing cholangiocarcinoma.

In their discussion, Mahzar and Russo stated that the routinely use of Anali scores is limited because it would require additional training and time to calculate for radiologists. We disagree with this point. Anali scores are simple as they only include 3 and 2 items which are respectively: dilatation of intrahepatic bile duct, dysmorphism, portal hypertension and dysmorphism, parenchymal enhancement heterogeneity after GBCA^{5, 6}. These items are routinely assessed during the interpretation of MRC. Ranging from 0 to 5 and 0 to 2, Anali scores are easy to calculate^{5,6}. The inter-observer reliability remains to be assessed but should be good among expert radiologists, who interpret most MRC of PSC patients.

Finally, Anali scores are predictors of clinical outcomes in PSC patients and are a promising tool to be used easily in clinical practice.

Financial support: none.

Conflicts of interest: The authors have no conflict to report.

Bibliography

1. Mazhar A, Russo MW. Systematic review: non-invasive prognostic tests for primary sclerosing cholangitis. *Aliment Pharmacol Ther* 2021;53:774-783.
2. Lazaridis KN, LaRusso NF. Primary Sclerosing Cholangitis. *N Engl J Med* 2016;375:1161-70.
3. Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. *Hepatology* 2013;58:2045-55.
4. Corpechot C, Gaouar F, El Naggat A, et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. *Gastroenterology* 2014;146:970-9; quiz e15-6.
5. Ruiz A, Lemoine S, Carrat F, et al. Radiologic course of primary sclerosing cholangitis: assessment by three-dimensional magnetic resonance cholangiography and predictive features of progression. *Hepatology* 2014;59:242-50.
6. Lemoine S, Cazzagon N, El Mouhadi S, et al. Simple Magnetic Resonance Scores Associate With Outcomes of Patients With Primary Sclerosing Cholangitis. *Clin Gastroenterol Hepatol* 2019;17:2785-2792 e3.
7. Cazzagon N, Lemoine S, El Mouhadi S, et al. The Complementary Value of Magnetic Resonance Imaging and Vibration-Controlled Transient Elastography for Risk Stratification in Primary Sclerosing Cholangitis. *Am J Gastroenterol* 2019;114:1878-1885.
8. Eaton JE, Vesterhus M, McCauley BM, et al. Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning. *Hepatology* 2020;71:214-224.
9. Ali AH, Tabibian JH, Nasser-Ghods N, et al. Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis. *Hepatology* 2018;67:2338-2351.
10. Schramm C, Eaton J, Ringe KI, et al. Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group. *Hepatology* 2017;66:1675-1688.